ArticleScientific reports2024
Transition from opportunistic cytological to organized screening program with DNA-HPV testing detected prevalent cervical cancers 10 years in advance.
Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Early effects of HPV vaccination on high-grade cervical intraepithelial neoplasia in Brazil: Evidence from outpatient data.Human vaccines & immunotherapeutics · 2026Article
- Assessing the burden of HPV-associated cancers in Brazil: Hospitalization and mortality trends from 2011 to 2019.Human vaccines & immunotherapeutics · 2026Article
- Performance of the cervical cancer screening program in Souss-Massa, Morocco: evidence for strategic transition toward HPV testing.BMC women's health · 2026Article
- Beyond Human Papillomavirus (HPV): Detection of EBV and Polyomaviruses in Cervical and Anal Samples.Journal of medical virology · 2026Article
- Swede Score can predict high-grade cervical intraepithelial neoplasia without previous cytology in colposcopies with transformation zone types 1 or 2.BMC women's health · 2026Article
- Age distribution of high-risk HPV infection and cervical lesions in an unvaccinated adult Brazilian population within an organized screening program.Scientific reports · 2026Article
- [Estimated number of procedures for implementing organized screening with HPV-DNA testing in BrazilEstimaciones de procedimientos para la implementación del rastreo organizado con pruebas de ADN del VPH en Brasil].Revista panamericana de salud publica = Pan American journal of public health · 2026Article
- Clinical Performance of a Liquid Preservation Medium for Cervicovaginal Samples in DNA-HPV Testing and Liquid-Based Cytology for Cervical Cancer Screening.Cytopathology : official journal of the British Society for Clinical Cytology · 2025Article
- Impact of government-organized screening programs on the economic burden of cervical cancer across five disease courses: a multistage regression and mediation analysis.Cancer biology & medicine · 2025Article
- Comparative clinical performance of Alinity m HR HPV, cobas 4800 HPV, and cobas 6800 HPV for cervical cancer screening.Microbiology spectrum · 2025Article
- Human papillomavirus infection and screening strategies.World journal of clinical oncology · 2025Review
- A Comparative Study of Conventional Pap Smear and Liquid-Based Cytology.Health science reports · 2025Article
- Addressing Global Disparities in Cervical Cancer Burden: A Narrative Review of Emerging Strategies.Current HIV/AIDS reports · 2025Review
- [Cervical cancer screening in Brazil: a coverage analysis using the Brazilian Cancer Information System].Cadernos de saude publica · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cervical cancer screening in Brazil is opportunistic, based on cytology and offered for women aged 25-64 years, with low coverage (30%) and 70% of cancer diagnoses done in advanced stages, without impact on mortality. The current study reports 5-year first-round results of a population-based DNA-HPV testing screening program in a Brazilian city, which intended to be a model for transition to a more efficient program. Program flowchart is simple and current, indicating repetition of a negative test after five years. The first-round (October 2017-September 2022) screened 20,551 women by DNA-HPV testing with 58.7% coverage and 99.4% compliance with the program's targeted age range. Coverage increases to 77.8% when excluding the 'pandemic period'. The DNA-HPV testing was 87.2% negative with 6.2% colposcopy referrals and 84.8% colposcopies performed. A total of 258 high-grade precursor lesions and 29 cervical cancers (mean age = 41.4 years, 83% Stage I) were detected. As a reference, 41,387 cytology tests from the previous program (2012-2016) detected 36 cervical cancers (mean age = 52.0 years, p = 0.0005), with 67% in advanced stages (p < 0.0001). Organizing cervical cancer screening using DNA-HPV testing demonstrated good coverage, high age and colposcopy compliance, and detection of more precancerous lesions and cervical cancers 10 years in advance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.